Exploring the past, present and future of regenerative medicine

Future Science Group (FSG) is excited to announce the release of the 10-Year Anniversary Special Focus Issue of Regenerative Medicine entitled "Regenerative medicine: past, present and future", which reflects on how the field has changed in the past 10 years.

The special issue takes a look at the past decade in regenerative medicine and provides an overview and perspectives on the progress being made in the field as a whole, as well as in a number of more specific areas including cellular therapy, genome editing, pluripotent stem cell research, ligament regenerative engineering, nanotechnology, immunogenicity and regenerative pharmacology. The issue also provides insight into major institutions involved in the field of regenerative medicine, describing their history, current work and plans for the future.

The Special Focus Issue has been guest edited by Robert Lanza (Astellas Institute for Regenerative Medicine, MA, USA), who serves as one of the journal's Associate Editors. Lanza provided a scene-setting foreword for the issue where he looks back at the last decade in regenerative medicine and describes some of the incredible progress made in the field. He then goes on to provide an overview of the wide variety of work presented in the issue including reviews, perspectives and special reports, amongst others.

Lanza concludes: "The field of regenerative medicine has continued to grow and change rapidly in the past 10 years. We believe that these articles help highlight important advances that have occurred, and that are likely to impact the future success of the field. The publication of this special issue celebrates an exciting milestone for Regenerative Medicine - the tenth year anniversary of the journal. I hope you will join me in congratulating the journal for reaching this major milestone."

Commissioning Editor for Regenerative Medicine Adam Price-Evans commented: "Bursting on to the scene in 2006 with the ALPSP/Charlesworth Award for Best New Journal, Regenerative Medicine has remained at the forefront of the field for the past decade. The journal continues to showcase the latest research and expert commentary from leaders in the field of regenerative medicine and we look forward to the next ten years."

Regenerative Medicine is part of the internationally recognized Future Medicine portfolio and is supported by a multidisciplinary, international editorial board comprising leading researchers and opinion leaders from academia and industry, including Senior Editor Chris Mason (UCL, UK), and Associate Editors Phillipe Menasché (Hôpital Européen Georges Pompidou, FR), Gail Naughton (Histogen Inc., CA, USA) and the aforementioned Robert Lanza.

Regenerative Medicine focusses on the entire spectrum of approaches in regenerative medicine, including small molecule drugs, biologics, biomaterials, tissue engineering, and cell and gene therapies. The peer-reviewed journal uniquely supports this important area of biomedical science and healthcare by publishing the very best regenerative medicine research and opinion, encompassing all aspects of the sector ranging from discovery research, to clinical development and commercialization.

Regenerative Medicine is committed to high-quality scholarly publications, operating a double-blind peer review system, and ensures that all original research and review articles are assessed by a minimum of three experts. It is also committed to supporting authors after publication, and partner with the award-winning Kudos to help authors increase the reach of their published articles. The journal is also partnered with RegMedNet, a free eCommunity aiming to promote global collaboration between all members of the regenerative medicine field as well as keep users up to date with the latest news and opinion, by providing exclusive features, webinars and more. Find out more: http://www.futuremedicine.com/loi/rme

Call for papers

The journal is currently inviting submissions of original research, review and perspective pieces, as well as shorter pieces such as editorials and organizational profiles. Submissions are being accepted via the journal's online submission site. Alternatively, authors are invited to direct any article proposals or general queries to the Commissioning Editor, Adam Price-Evans at a.price-evans@futuremedicine.com.

About Future Science Group (FSG)

Founded in 2001, London-based FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to the core journal publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, RegMedNet, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. Please see http://www.futuresciencegroup.com and http://www.futuremedicine.com for more information.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.